share_log

Wedbush Maintains Outperform on Astria Therapeutics, Lowers Price Target to $18

Benzinga ·  Oct 13, 2023 11:22

Wedbush analyst Laura Chico maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and lowers the price target from $25 to $18.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment